Journal: Communications Biology
Article Title: CD25 modulation enhances broadly neutralizing antibody response of SARS-CoV-2 subunit vaccine
doi: 10.1038/s42003-026-09721-9
Figure Lengend Snippet: A BALB/c mice received bilateral subcutaneous injection with G1: vaccine (Antigen/PMO 10 μg:100 μg), G2 and G3: 200 μg anti-CD25 mAb and vaccine (Antigen/PMO 10 μg:100 μg). Blood collection was performed 2 weeks after each immunization ( n = 7). Mice were sacrificed three weeks after the third immunization for draining lymph node and spleen analysis ( n = 4). B RBD-specific IgG titers of BALB/c mice serum at 2, 5, 8 ( n = 7) and 13 weeks ( n = 3). Error bars in the figure indicate geometric mean. C Geometric mean neutralizing antibody titers (ID50) against WT (D614G), B1.1.7, B.1.351, P.1, B.1.617.2, BA.1, BA.2, BA.4/5, and BA.2.75 at 8 weeks post-immunization. Pre-immune sera were evaluated to confirm that there were no non-specific effects on viral entry ( n = 7). B , C Error bars in the figure indicate geometric mean. Data are represented as geometric means ± geometric SEM. D B cells in live cells percentages. E GC B cells in B cells and RBD-specific GC B cells in GC B cells representative flow cytometry, percentages, and absolute counts per million. F Plasma absolute counts per million. G Treg absolute counts per million. H Tfh and Tfr cells in CD4 + T percentages and absolute counts per million. I Schematic diagram. J The frequencies of CD69 + IFN-γ + in CD4 + T and CD8 + T cells. K Representative figures and quantification of ELISPOT. All error bars in the figures indicate SEM. Data are represented as means ± SEM. All P values are from one-way ANOVA followed by Tukey’s multiple comparisons test.
Article Snippet: To investigate the early-stage immune response to Anti-CD25 mAb (InVivoMAb anti-mouse CD25 IL-2Rα, Clone PC-61, BE0012, bioxcell), BALB/c mice were bilaterally injected with a total volume of 100 μL vaccine (each side 50 μL vaccine) and near the vaccine site a total volume of 100 μL of 200 μg anti-CD25mAb (each side 50 μL of 200 μg anti-CD25mAb) on day 0, draining lymph nodes were harvested at 1, 3-, 6-, 9-, and 12-days post-injection for flow cytometry analysis.
Techniques: Injection, Flow Cytometry, Clinical Proteomics, Enzyme-linked Immunospot